- Speaker presentation
- Open Access
Digital health, microfluidics, and bedside genetic testing
© Hashsham; licensee BioMed Central Ltd. 2014
- Published: 21 January 2014
- Microfluidic Chip
- Specific Language
- Solar Panel
- Disease Surveillance
- Cost Approach
Decentralized, bedside, or point of care analysis of nucleic acids (DNA/RNA/mRNA/microRNA)-based markers is expected to be a key component of digital healthcare. Nucleic acids-based approaches allow for screening of disease and pathogens, disease surveillance, selection of treatment, treatment effectiveness, differential diagnosis, risk assessment, staging, and prognosis. Hand-held genetic analysis systems have the potential to provide all these capabilities in a simple, affordable, field deployable, rapid, multiplexed, and robust manner without the need for electrical power or refrigerated reagents. Even the need for specific language can be eliminated by translatable or visual graphical user interface truly integrating the analytical system with the communication network.
The presentation will introduce Gene-Z and iDx, two networkable platforms that are developed to provide simplified analysis of genetic markers. Gene-Z has Android/iPod based operation using BluetoothTM and capable of carrying out quantitative isothermal amplification for 64 reactions in a disposable microfluidic chip. The device is battery operated and can be charged by solar panels integrated at the top of the device. A smaller version (iDx) working as an attachment to cell phones, also with real time amplification and quantification capabilities, allows 8 reactions in parallel. Both these devices are networkable and currently being validated for a number of key applications important to human and animal health, plant safety, industrial microbiology, and environmental protection. Simplification, reliability, and cost-effectiveness are key factors ensuring successful implementation of such approaches. Business model for adoption of such low cost approaches, however, is still evolving and major challenges need to be addressed about how to sustain a business that is built on small margins usually by small companies engaged in biomedical research.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.